<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04204382</url>
  </required_header>
  <id_info>
    <org_study_id>ZDKS-CP-180503-V1.1</org_study_id>
    <nct_id>NCT04204382</nct_id>
  </id_info>
  <brief_title>Effects of CKI for Oral Mucositis Caused by Radiotherapy for Head and Neck Cancer</brief_title>
  <official_title>Clinical Study of the Effects of Compound Kushen Injection on Radiation-induced Oral Mucositis in Head and Neck Cancer Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanxi Zhendong Pharmacy Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanxi Zhendong Pharmacy Co., Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oral mucositis (OM) is an acute side effect of radiotherapy for head and neck cancer (HNC).&#xD;
      OM associated pain affects oral functions and nutrition of the patient that may result in&#xD;
      discontinuity of treatment.The purpose of this clinical study is to evaluate the therapeutic&#xD;
      effects of Compound Kushen Injection (CKI) on oral mucositis caused by radiotherapy of head&#xD;
      and neck cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with oral mucositis caused by radiotherapy for Head and Neck Cancer，will be enrolled&#xD;
      in the trial, then seprated randomly in two group,the experimental group treated with&#xD;
      Levofloxacin injection plus CKI; the contral group treated with Levofloxacin injection only.&#xD;
      Clinical grade of radioactive oral mucositis，Oral pain score，Completion and duration of&#xD;
      interruption of radiotherapy， Completion of chemotherapy during concurrent&#xD;
      chemoradiotherapy，weight change，Food intake (liquid food, semi liquid food)，recovery time of&#xD;
      oral mucositis will be compared before treatment, 3 days, 5 days and 7 days after treatment&#xD;
      between the experimental group and the control group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 12, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical grade of radioactive oral mucositis</measure>
    <time_frame>From baseline to day 7.</time_frame>
    <description>Treatment efficacy measured by Chinese guideline &quot;Clinical diagnosis and treatment guidelines for tumor&quot;&#xD;
Significant: no leukoplakia or ulcer of the oral mucosa, mild hyperemia(grade Ⅰ), able to eat regular diet.&#xD;
Effective: moderate hyperemia of the oral mucosa, mild leukoplakia or patchy ulcerations(grade Ⅱ)，semi fluid intake, but not interfering with radiotherapy.&#xD;
Ineffective: severe hyperemia of the oral mucosa, flaked leukoplakia or ulcer (grade III or above), fluid intake，severe symptoms interfering with radiation therapy , intravascular nutrition or antibiotic treatment.&#xD;
Total effective rate = (significant + effective) / total cases × 100%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oral pain score</measure>
    <time_frame>From baseline to day 7.</time_frame>
    <description>Oral pain are evaluated with Visual Analogue Score (VAS): 0 equal no pain and 10 equal worst imaginable pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Completion of radiotherapy during concurrent radiotherapy</measure>
    <time_frame>From baseline to day 7.</time_frame>
    <description>Compare the proportion of patients completing radiotherapy between the two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of interruption of radiotherapy</measure>
    <time_frame>From baseline to day 7.</time_frame>
    <description>Compare the days of interruption period of radiotherapy between the two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Completion of chemotherapy during concurrent chemoradiotherapy</measure>
    <time_frame>From baseline to day 7.</time_frame>
    <description>Compare the proportion of patients whom complete chemotherapy between the two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight change</measure>
    <time_frame>From baseline to day 7.</time_frame>
    <description>Compare the reduction in mean weight during radiotherapy between the two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Food intake (liquid food, semi liquid food)</measure>
    <time_frame>From baseline to day 7.</time_frame>
    <description>Compare intake ability of food (liquid food, semi liquid food) between the two groups.&#xD;
Effective:dietary has improved (for example, changing from liquid food to semi liquid food, from semi liquid food to soft food, or from soft food to regular diet) Ineffective: the patients can not eat, or need tube feedings, or parenteral nutrition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recovery time of oral mucositis</measure>
    <time_frame>From baseline to day 7.</time_frame>
    <description>Recovery time，defined as the days needs for the clinical grade of oral mucositis to fall to grade II.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Radiation-induced Oral Mucositis</condition>
  <arm_group>
    <arm_group_label>test group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CKI was injected intravenously for 7 days, once a day, 20ml each time；&#xD;
Levofloxacin injection were injected intravenously for 7 days, once a day, 0.5g each time,</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Levofloxacin injection were injected intravenously for 7 days, once a day, 0.5g each time.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin Injection</intervention_name>
    <description>Levofloxacin Injection 0.5 g each time, once a day, intravenous drip.Treatment course is 7 days.</description>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>test group</arm_group_label>
    <other_name>Zuoyangfushaxing Zhusheye</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Compound Kushen Injection（CKI）</intervention_name>
    <description>CKI, 20mL each time, once a day, intravenous drip. Treatment course is 7 days.</description>
    <arm_group_label>test group</arm_group_label>
    <other_name>Yanshu injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients are pathologically diagnosed as stage III or stage Ⅳ squamous cell carcinoma&#xD;
             of head and neck cancer (including nasopharyngeal carcinoma)and are in accordance with&#xD;
             the diagnostic criteria of radiotherapy induced mucositis/ stomatitis;&#xD;
&#xD;
          2. Patients have no prior history of radiotherapy, and grade III oropharyngeal mucositis&#xD;
             occured after the first radiotherapy;&#xD;
&#xD;
          3. Patients have no stomatological diseases such as ulcer, edema and exudation in the&#xD;
             oropharyngeal mucosa before radiotherapy;&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance Score is 0 or 1;&#xD;
&#xD;
          5. The function of each organ is basically normal, including: hemoglobins ≥ 9g/dL,&#xD;
             platelets ≥ 80×10^9/L, leukocytes ≥ 3×10^9/L, liver function within 3 times the upper&#xD;
             normal limit, creatinine clearance ≥ 60mL/min;&#xD;
&#xD;
          6. Patients aged between 18 and 75 years;&#xD;
&#xD;
          7. Patients have a life expectancy of at least 6 months;&#xD;
&#xD;
          8. Patients have fully understood the study and signed the informed consent voluntarily&#xD;
             prior to any related procedures of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have received CoKS or systemic antibiotic treatment within 2 weeks before&#xD;
             treatment;&#xD;
&#xD;
          2. Patients who have a history of head or neck surgery (except biopsy);&#xD;
&#xD;
          3. Female patients who are pregnant or breast feeding or female of pregnancy potential&#xD;
             with a positive pregnancy test before treatment;&#xD;
&#xD;
          4. Patients with serious or uncontrolled organic diseases or infections, such as&#xD;
             decompensate cardiac function failure, pulmonary function failure, liver function&#xD;
             failure, renal function failure, causing unability to tolerate radiotherapy;&#xD;
&#xD;
          5. Patients who have radiotherapy contraindications;&#xD;
&#xD;
          6. Patients who are allergic to the study medications or quinolones;&#xD;
&#xD;
          7. Patients have serious psychological or psychiatric disorders, drug abuse or alcohol&#xD;
             dependence in the past;&#xD;
&#xD;
          8. Patients are currently participating in another clinical study or have participated in&#xD;
             another clinical trial in the past 30 days;&#xD;
&#xD;
          9. The investigator believes that it is not appropriate to participate in this trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xin-xin Zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xin-xin Zhang</last_name>
    <phone>15910520109</phone>
    <email>xinxinzhang66@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin-xin Zhang</last_name>
      <phone>15910520109</phone>
      <email>xinxinzhang66@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-Sen Memorial Hospital Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yue Bei People's Hospital</name>
      <address>
        <city>Shaoguan</city>
        <state>Guangdong</state>
        <zip>512025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henan Anyang Tumor Hospital</name>
      <address>
        <city>Anyang</city>
        <state>Henan</state>
        <zip>455001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nanyang Central Hospital</name>
      <address>
        <city>Nanyang</city>
        <state>Henan</state>
        <zip>473009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zhenzhou Central Hospital</name>
      <address>
        <city>Zhenzhou</city>
        <state>Henan</state>
        <zip>450007</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhenzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Jiangsu University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>212000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Liaoning Cancer Hospital &amp; Institue</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Haici Medical Group</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Weihai Municipal Hospital</name>
      <address>
        <city>Weihai</city>
        <state>Shandong</state>
        <zip>264200</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Second hospital of Shanxi Medical University</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 12, 2019</study_first_submitted>
  <study_first_submitted_qc>December 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2019</study_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Mucositis</mesh_term>
    <mesh_term>Stomatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

